GeoVax to Showcase Vaccine and Immunotherapy Progress at Emerging Growth Conference
July 14th, 2025 1:00 PM
By: Newsworthy Staff
GeoVax Labs, Inc. will present updates on its GEO-MVA, GEO-CM04S1, and Gedeptin® programs at the Emerging Growth Conference, highlighting advancements in vaccine development and cancer therapy.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on July 16, 2025. The presentation will focus on the company's pipeline, including the GEO-MVA vaccine for Mpox/smallpox, which has received favorable feedback from the European Medicines Agency, the GEO-CM04S1 COVID-19 vaccine undergoing Phase 2 trials, and Gedeptin®, a therapy for solid tumors entering a Phase 2 trial for head and neck cancer.
David Dodd, GeoVax's Chairman and CEO, will discuss these programs and how the company's MVA platform and manufacturing capabilities address vaccine supply and biosecurity challenges. The event offers a live Q&A session for participants to engage directly with the company's leadership.
For those interested in attending, registration is available here. Questions can be submitted in advance or during the presentation, with a replay available post-event on the Emerging Growth website and YouTube channel.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
